Loading…
Molecular Partners AG is projected to rise to $4.50 by 2027, a +11% move from its current price of $4.04. MOLN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.93 | $4.04 | $4.16 | +0.05% |
| May 30 | $3.89 | $4.04 | $4.21 | +0.10% |
| May 31 | $3.86 | $4.05 | $4.24 | +0.15% |
| Jun 1 | $3.83 | $4.05 | $4.28 | +0.20% |
| Jun 2 | $3.81 | $4.05 | $4.31 | +0.25% |
| Jun 3 | $3.79 | $4.05 | $4.34 | +0.30% |
| Jun 4 | $3.77 | $4.05 | $4.36 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.77 | $4.05 | $4.36 | +0.35% |
| Week 2 | $3.67 | $4.07 | $4.51 | +0.71% |
| Week 3 | $3.60 | $4.08 | $4.63 | +1.07% |
| Week 4 | $3.54 | $4.10 | $4.74 | +1.42% |
| Week 5 | $3.49 | $4.11 | $4.84 | +1.78% |
| Week 6 | $3.45 | $4.13 | $4.94 | +2.14% |
| Week 7 | $3.41 | $4.14 | $5.02 | +2.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Molecular Partners AG is a clinical-stage biotechnology company that designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. It operates in the Healthcare sector.
Its pipeline includes MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.
It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Molecular Partners AG (MOLN) is a biotechnology company focused on designing DARPin therapeutics for oncology. It currently trades with a price of $4.18 and carries a market cap of $156.8M, ranking 3999.
The stock trades near key technical levels, with SMA50 at $4.19 and SMA200 at $4.14. Near-term support sits at $3.74 and resistance at $4.46. The 30-day price range spans from $3.46 to $5.05, and the market’s sentiment is NEUTRAL with an annualized volatility around 50%.
Forecasts depict a long-run upside, with 2026 averaging $4.18 and 2050 averaging $29.79, alongside a path of higher prices through 2040 and beyond; the projections show substantial upside with an eventual max around $56.13 in 2050 and corresponding ROI figures that rise markedly over time.
A major floor 16.8% below — a decisive break under it would weaken the trend.
The nearest floor, 7.4% below — buyers have tended to step in here.
The nearest ceiling, 10.4% above — a clean break opens room to run.
A major ceiling 26.9% above — clearing it would confirm fresh momentum.
Key MOLN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MOLN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.96 | Buy | $3.99 | Buy |
| MA 10 | $3.90 | Buy | $3.98 | Buy |
| MA 20 | $4.06 | Sell | $4.04 | Buy |
| MA 50 | $4.18 | Sell | $4.18 | Sell |
| MA 100 | $4.36 | Sell | $4.24 | Sell |
| MA 200 | $4.14 | Sell | $4.25 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.40 | Neutral |
| Stoch RSI (14) | 75.10 | Neutral |
| CCI (20) | -8.85 | Neutral |
| Williams %R (14) | -31.82 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -1.46 | Sell |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 68.18 | Neutral |
| TRIX (15) | -0.34 | Sell |
| Awesome (5,34) | -0.20 | Sell |
| Ultimate (7,14,28) | 55.06 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 4.11 | Sell |
| ADX (14) | 15.79 | Neutral |
| ATR (14) | 0.09 | Info |
The near-term technical picture is NEUTRAL. The RSI14 sits at 50, and the stock trades around the midpoints of its major moving averages, with SMA50 at $4.19 and SMA200 at $4.14.
The 30-day range runs from $3.46 to $5.05, providing a defined trading band. Support is at $3.74 and resistance at $4.46, framing potential short-term moves within that corridor.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.74 | $4.04 | $5.65 | 0% | Neutral | |
| $3.56 | $4.50 | $6.02 | +11% | Neutral | |
| $3.90 | $5.06 | $7.02 | +25% | Bullish | |
| $3.84 | $5.10 | $7.28 | +26% | Bullish | |
| $4.32 | $5.86 | $8.57 | +45% | Bullish | |
| $5.29 | $7.31 | $10.91 | +81% | Bullish | |
| $5.41 | $7.60 | $11.57 | +88% | Bullish | |
| $5.95 | $8.50 | $13.15 | +110% | Bullish | |
| $6.08 | $8.82 | $13.87 | +118% | Bullish | |
| $5.60 | $8.25 | $13.17 | +104% | Bullish | |
| $8.51 | $13.41 | $22.78 | +232% | Bullish | |
| $14.44 | $25.58 | $47.53 | +533% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.74 | $4.04 | $4.73 | +0.00% |
| June 2026 | $3.47 | $4.08 | $4.91 | +1.00% |
| July 2026 | $3.57 | $4.23 | $5.16 | +3.68% |
| August 2026 | $3.55 | $4.23 | $5.22 | +0.08% |
| September 2026 | $3.55 | $4.25 | $5.29 | +0.49% |
| October 2026 | $3.69 | $4.45 | $5.57 | +4.50% |
| November 2026 | $3.75 | $4.54 | $5.73 | +2.15% |
| December 2026 | $3.67 | $4.46 | $5.65 | -1.87% |
Click any year to see its month-by-month MOLN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The MOLN price prediction for 2026 points to an average of $4.04 (low $3.74, high $5.65) — a potential gain of 0% on today's $4.04. A consolidation phase looks the most probable path here.
In 2027, MOLN is projected to trade between $3.56 and $6.02, averaging $4.50 — a potential gain of +11% from today's $4.04. That is up +11% on the projected 2026 average. Price action looks broadly range-bound.
Molecular Partners AG's 2028 outlook centres on $5.06, within a $3.90 to $7.02 range. That is up +13% on the projected 2027 average. That marks a +25% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, MOLN could reach as high as $7.28, with a base case around $5.10 and support toward $3.84 — roughly +26% from $4.04. Momentum favours further upside here.
Expect MOLN to range from $4.32 to $8.57 through 2030. The $5.86 average target implies a +45% move from current prices. That is up +15% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The MOLN price prediction for 2031 points to an average of $7.31 (low $5.29, high $10.91) — a potential gain of +81% on today's $4.04. Momentum favours further upside here.
In 2032, MOLN is projected to trade between $5.41 and $11.57, averaging $7.60 — a potential gain of +88% from today's $4.04. That is up +4% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Molecular Partners AG's 2033 outlook centres on $8.50, within a $5.95 to $13.15 range. That is up +12% on the projected 2032 average. That marks a +110% change versus current levels. Momentum favours further upside here.
By 2034, MOLN could reach as high as $13.87, with a base case around $8.82 and support toward $6.08 — roughly +118% from $4.04. Buyers look set to stay in control over this stretch.
Expect MOLN to range from $5.60 to $13.17 through 2035. The $8.25 average target implies a +104% move from current prices. That is -6% versus the projected 2034 average. Momentum favours further upside here.
The MOLN price prediction for 2040 points to an average of $13.41 (low $8.51, high $22.78) — a potential gain of +232% on today's $4.04. Buyers look set to stay in control over this stretch.
In 2050, MOLN is projected to trade between $14.44 and $47.53, averaging $25.58 — a potential gain of +533% from today's $4.04. That is up +91% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in MOLN today (≈ 247.524752 MOLN) could be worth
$6,331.2
+$5,331.2 (+533%) by 2050 · US Dollar
Based on the average projected MOLN price of $25.58 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MOLNwould be worth at today's price.
$1,000 invested in MOLN on May 27, 2025 (≈ 246.305422 MOLN) would be worth
$995.07
-$4.93 (-0.5%) today · 1.00× · US Dollar
Based on a MOLN entry price of $4.06 vs. today's $4.04.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.74 | $1,080.21 | +8.0% |
| 1 month ago | $4.35 | $928.74 | -7.1% |
| 3 months ago | $4.88 | $827.87 | -17.2% |
| 6 months ago | $4.12 | $980.11 | -2.0% |
| 1 year ago | $4.06 | $995.07 | -0.5% |
| All time (4.9y) ago | $19.65 | $205.6 | -79.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MOLN forecast.
Our base-case forecast reaches $8.10 around 2033.
Implied market cap at $8.10: $303.84M
The multi-year forecast lays out a bullish trajectory with rising average prices and meaningful upside by mid-century. The year-by-year path starts with 2026 at an average of $4.18 and climbs through 2030 to an average of $6.41, then advances to $8.03 in 2031 and $8.35 in 2032 before continuing higher to $29.79 on average by 2050.
Projected returns (ROI) follow a similar arc, from 0 in 2026 to 53.4 in 2030, 92.2 in 2031, 99.8 in 2032, 125.8 in 2033, 133.3 in 2034, 117.8 in 2035, 263.3 in 2040, and 612.6 by 2050. The longer horizon suggests substantial upside, albeit with the usual uncertainties and the condition that these are estimates, not guarantees. Drivers and risks are not listed explicitly in the data, so investors should weigh the projected path against their own analysis and market conditions.
Tap a question to reveal the answer.
2030 min $4.70, avg $6.41, max $9.45 with ROI 53.4. This year shows a clear higher-price expectation compared with 2026 and 2027 forecasts.
The forecasts show a bullish trajectory with higher averages through 2050 (e.g., 2040 avg $15.19 and 2050 avg $29.79; ROI to 612.6). These are estimates, not guarantees, and should be weighed with risk and market factors.
Yes. The forecast includes 2031 max $12.10 and 2032 max $12.83, indicating potential to exceed $12 in those years.
Current price is $4.18 and market cap is $156.8M.
RSI14 is 50 with sentiment NEUTRAL. SMA50 is $4.19 and SMA200 is $4.14. The 30-day range is $3.46 to $5.05, with near-term support at $3.74 and resistance at $4.46.
Molecular Partners AG Community Discussion
0Share your Molecular Partners AG price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.